首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains.
【24h】

Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains.

机译:头孢曲松和利奈唑胺联合治疗肺炎球菌性脑膜炎:该病例系列包括耐青霉素菌株。

获取原文
获取原文并翻译 | 示例
           

摘要

This study evaluated the role of linezolid in the treatment of patients suffering from pneumococcal meningitis. Treatment included ceftriaxone (4000 mg every 24 h), linezolid (600 mg every 12 h) and dexamethasone (8 mg every 6 h). Linezolid was withdrawn if a penicillin-susceptible isolate of Streptococcus pneumoniae was identified. Of 16 patients studied, seven were infected with penicillin-non-susceptible isolates of S. pneumoniae, two died, and three reported sequelae. No toxicity was reported. It was concluded that linezolid can be used for the treatment of pneumococcal meningitis, as an alternative to vancomycin or rifampicin, in regimens including a third-generation cephalosporin.
机译:这项研究评估了利奈唑胺在治疗肺炎球菌性脑膜炎患者中的作用。治疗包括头孢曲松(每24小时4000毫克),利奈唑胺(每12小时600毫克)和地塞米松(每6小时8毫克)。如果鉴定出对青霉素敏感的肺炎链球菌分离株,则撤回利奈唑胺。在研究的16例患者中,有7例感染了非青霉素肺炎链球菌分离株,其中2例死亡,3例报告了后遗症。没有毒性的报道。结论是,在包括第三代头孢菌素在内的治疗方案中,利奈唑胺可代替其他万古霉素或利福平用于肺炎球菌性脑膜炎的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号